Lv42
420 积分 2024-01-09 加入
Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis
6小时前
已完结
Next-Generation Sequencing Liquid Biopsy-Guided Osimertinib Rechallenge in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients
6小时前
已完结
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
1天前
已完结
Discrepancy Between Radiological and Pathological Tumor Size in Early-Stage Non-Small Cell Lung Cancer: A Multicenter Study
8天前
已完结
Adjuvant Chemotherapy for High-risk Pathologic Stage I Non-Small Cell Lung Cancer
8天前
已完结
High-Risk Features Associated with Recurrence in Stage I Lung Adenocarcinoma
9天前
已完结
Clinical Impacts of EGFR Mutation Status: Analysis of 5780 Surgically Resected Lung Cancer Cases
9天前
已完结
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes
16天前
已完结
Successful Treatment with Osimertinib and Chemotherapy in a Non–Small Cell Lung Cancer Patient with EGFR Mutation and Meningeal Carcinomatosis
16天前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
22天前
已完结
皖公网安备34019202002308
